Antihypertensive combination use warning

The MHRA has warned healthcare professionals about the risk of hyperkalaemia, hypotension and renal impairment when different classes of drugs that inhibit the renin-angiotensin system are used in combination.

RAS-blocking agents are used to treat hypertension and congestive heart failure (pictured). | SCIENCE PHOTO LIBRARY
RAS-blocking agents are used to treat hypertension and congestive heart failure (pictured). | SCIENCE PHOTO LIBRARY

Drugs that act on the renin-angiotensin system (RAS) include:

Following an EU review (including data from the ONTARGETALTITUDE and VA NEPHRON-D studies and a meta-analysis by Makani), healthcare professionals are advised not to prescribe an ACE inhibitor in combination with an ARB in patients with diabetic nephropathy as these individuals are already at risk of developing hyperkalaemia.

Candesartan and valsartan are licensed as add-on therapy to ACE inhibitors for people with symptomatic heart failure who require such a combination despite optimal therapy. Combination therapy should be limited to patients intolerant of mineralocorticoid antagonists and with persistent symptoms despite other optimal therapy. The triple combination of an ACE inhibitor, ARB, and a mineralocorticoid receptor antagonist or other potassium-sparing diuretic is not recommended.

Aliskiren in combination with an ACE inhibitor or ARB is contraindicated in patients with renal impairment (eGFR <60ml/min/1.73m2) or diabetes.

Patients currently on combination treatment

Individuals currently receiving combination therapy with RAS-blocking agents should be reassessed at their next routine appointment to determine the need for ongoing treatment.

If combination treatment is necessary, it must be carried out under specialist supervision with blood pressure, renal function and electrolytes monitored at the start of therapy and monthly thereafter, as well as after any dose change and during intercurrent illness.

MHRA Drug Safety Update June 2014

Follow MIMS on Twitter

Sign up to MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in